A Major Partnership to Create a New Vaccine Using mRNA Technology
Korea University and the pharmaceutical company Moderna announced in July 2024 that they are working together to develop a new vaccine. The vaccine will use a technology called mRNA, which made headlines during the COVID-19 pandemic. This time, they are applying it to a virus called hantavirus, which causes illness in parts of Asia.
What Is mRNA and Why Does It Matter?
To understand why this partnership matters, it helps to know what mRNA technology does. Traditional vaccines often contain a weakened or inactive version of a virus. An mRNA vaccine works differently. It carries genetic instructions that tell your immune system how to recognize and fight a virus — without the virus itself being present.
Think of it like sending your immune system a wanted poster, rather than asking it to study a captured criminal. Your body reads these instructions, builds copies of a protein from the virus, and then learns to recognize and attack that protein if it encounters the real thing later.
During the COVID-19 pandemic, mRNA vaccines from Moderna and other companies proved this approach could work quickly and safely. Now companies and research centers are exploring whether the same technology can fight other diseases.
The Korean Connection
Korea University's Vaccine Innovation Center, led by Professor Kim Woo-joo, has worked on infectious disease responses for years. The center's hospital has been on the front lines during outbreaks of swine flu, MERS, and COVID-19. This real-world experience gives the university credibility in understanding how diseases spread and what protection people need.
Moderna brings a different strength: it has already built the factories, procedures, and regulatory approvals needed to manufacture mRNA vaccines at large scale. The partnership pairs Korea University's disease expertise with Moderna's proven ability to make vaccines and get them approved by regulators.
The Science So Far
Researchers working with Korea University recently published early results in Nature Communications testing three different vaccine approaches against hantavirus. They tested an mRNA version, a DNA version, and a DNA version wrapped in tiny fat particles.
In laboratory tests using mice, the mRNA version triggered a strong immune response. The DNA wrapped in fat particles created high levels of antibodies — proteins that help your body fight infection. All three approaches worked about as well as existing hantavirus vaccines.
These results are encouraging enough that researchers think mRNA is worth trying in actual human studies.
Why Hantavirus?
Hantavirus is not well known in most of the world, but it is a real threat in parts of East Asia, including Korea. The virus causes a serious illness called hemorrhagic fever with renal syndrome, which attacks the kidneys and can be deadly. There is no cure once someone gets infected, so prevention through vaccination is important.
The reason no one has made a widely available hantavirus vaccine before is partly economic. A vaccine company needs to sell enough doses to cover the cost of development. Hantavirus exists in limited regions, so a traditional vaccine might not be profitable enough to justify the investment.
mRNA technology changes this calculation. Once Moderna has built the factories and systems to make one mRNA vaccine, adding a new vaccine is faster and cheaper than developing a traditional vaccine from scratch. This means diseases that affect fewer people in specific parts of the world become worth pursuing.
What Comes Next
If the partnership succeeds, it would show that mRNA technology can address not just pandemic diseases that affect the whole world, but also regional diseases that matter deeply to specific populations. It would also strengthen South Korea's position in vaccine development — a goal the country has prioritized since COVID-19 exposed gaps in its vaccine supply.
For Moderna, it is another step in proving that mRNA is not a one-hit wonder, but a flexible platform that can be adapted to many different viruses.
The timeline from here involves human trials, regulatory review, and manufacturing scale-up — a process that could take years. But the foundation appears solid.
